{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:17:42Z","timestamp":1761967062132,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.biopha.2011.12.007","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T04:45:24Z","timestamp":1329885924000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic factors for therapy-related acute myeloid leukaemia (t-AML) \u2013 A single centre experience"],"prefix":"10.1016","volume":"66","author":[{"given":"Nada","family":"Suvajd\u017ei\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zorica","family":"Cvetkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"\u0110or\u0111evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Kraguljac-Kurtovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejana","family":"Stanisavljevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrija","family":"Bogdanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"\u0110juni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nata\u0161a","family":"\u010colovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vidovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Elezovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragica","family":"Tomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2011.12.007_bib0005","series-title":"WHO classification of tumours of hematopoietic and lymphoid tissues","first-page":"127","article-title":"Introduction and overview of the classification of the myeloid neoplasms","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.biopha.2011.12.007_bib0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2008.005157","article-title":"Therapy-related myeloid neoplasms","volume":"94","author":"Larson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2011.12.007_bib0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","article-title":"Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogenetic transplantation","volume":"13","author":"Armand","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.biopha.2011.12.007_bib0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2011.12.007_bib0025","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in therapy-related acute myeloid leukemia and impact of karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1309\/AJCP5ETHDXO6NCGZ","article-title":"Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome","volume":"131","author":"Gustafson","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0035","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2011.12.007_bib0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2362.2008.02041.x","article-title":"Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation","volume":"28","author":"Boehm","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.biopha.2011.12.007_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","article-title":"Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia","volume":"184","author":"Qian","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.biopha.2011.12.007_bib0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/10428190701769657","article-title":"Influence of DNA damage and repair upon the risk of treatment related leukemia","volume":"49","author":"Guillem","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2011.12.007_bib0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2006.06469.x","article-title":"Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia","volume":"136","author":"Bolufer","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","article-title":"Incidence and susceptibility to therapy-related myeloid neoplasms","volume":"184","author":"Leone","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.biopha.2011.12.007_bib0065","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0070","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.leu.2403947","article-title":"Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients","volume":"19","author":"Rund","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2011.12.007_bib0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cbi.2005.03.023","article-title":"Therapy-related myeloid leukaemia: a model for leukemogenesis in humans","volume":"153\u2013154","author":"Larson","year":"2005","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.biopha.2011.12.007_bib0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","article-title":"Reasons for treating secondary AML as de novo AML","volume":"85","author":"Ostg\u00e5rd","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0085","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4149\/neo_2010_02_170","article-title":"Secondary acute myeloid leukemia - a single center experience","volume":"57","author":"Szotkowski","year":"2010","journal-title":"Neoplasma"},{"key":"10.1016\/j.biopha.2011.12.007_bib0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of The Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0095","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1309\/MFCP-7GMW-AQM4-ED3N","article-title":"Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia","volume":"114","author":"Kraguljac","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0165-4608(94)90007-8","article-title":"Rapid method for obtaining high quality chromosome banding in the study of hemopoietic neoplasia","volume":"74","author":"Novak","year":"1994","journal-title":"Cancer Genet Cytogenet"},{"year":"2009","series-title":"ISCN 2009: an international system for human cytogenetics nomenclature","author":"Shaffer","key":"10.1016\/j.biopha.2011.12.007_bib0120"},{"key":"10.1016\/j.biopha.2011.12.007_bib0125","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0130","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA group","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0135","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0140","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1002\/cncr.25525","article-title":"Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma","volume":"116","author":"Gruschkus","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2011.12.007_bib0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3899\/jrheum.090834","article-title":"Azathioprine: association with therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"37","author":"Kwong","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1476-5381.2010.01100.x","article-title":"Therapy-related myeloid neoplasms; pathobiology and clinical characteristics","volume":"162","author":"Still","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0155","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation","volume":"95","author":"Pedersen-Bjergaard","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bmt.1705547","article-title":"Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?","volume":"39","author":"Hake","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2011.12.007_bib0165","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-06-1420","article-title":"Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up","volume":"12","author":"Brusamolino","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2011.12.007_bib0170","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2011.12.007_bib0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cancergencyto.2008.01.004","article-title":"Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis","volume":"182","author":"Ramkumar","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.biopha.2011.12.007_bib0180","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2008.002063","article-title":"The hematopietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome","volume":"94","author":"Zipperer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2011.12.007_bib0185","article-title":"Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia","author":"Djunic","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0190","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0195","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.2008.000927","article-title":"Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation","volume":"94","author":"Kr\u00f6ger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2011.12.007_bib0200","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2011.12.007_bib0205","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.12.007_bib0210","first-page":"393","article-title":"Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+\/DR--phenotypes with shorter survival. Groupe d\u2019\u00e9tude immunologique des leuc\u00e9mies (GEIL)","volume":"6","author":"Solary","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2011.12.007_bib0215","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/leu.2010.279","article-title":"Study Alliance Leukemia. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial","volume":"25","author":"St\u00f6lzel","year":"2011","journal-title":"Leukemia"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:49:56Z","timestamp":1760093396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0753332212000200"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2011.12.007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors for therapy-related acute myeloid leukaemia (t-AML) \u2013 A single centre experience","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2011.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}